Equities research analysts expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) to post ($0.33) earnings per share for the current quarter, Zacks reports. Five analysts have made estimates for Amicus Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.36) and the highest estimate coming in at ($0.31). Amicus Therapeutics reported earnings per share of ($0.31) in the same quarter last year, which would suggest a negative year over year growth rate of 6.5%. The company is scheduled to report its next quarterly earnings report on Monday, November 4th.
According to Zacks, analysts expect that Amicus Therapeutics will report full year earnings of ($1.47) per share for the current financial year, with EPS estimates ranging from ($1.58) to ($1.06). For the next year, analysts forecast that the firm will post earnings of ($1.03) per share, with EPS estimates ranging from ($1.33) to ($0.79). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Amicus Therapeutics.
Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.34). The business had revenue of $44.13 million for the quarter, compared to analysts’ expectations of $41.14 million. Amicus Therapeutics had a negative net margin of 336.41% and a negative return on equity of 66.79%. The company’s revenue for the quarter was up 107.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.33) EPS.
Several equities research analysts have commented on the stock. Cowen restated a “buy” rating and issued a $31.00 price target on shares of Amicus Therapeutics in a research note on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Amicus Therapeutics in a research report on Thursday, August 1st. BidaskClub lowered Amicus Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $19.00 target price (down from $20.00) on shares of Amicus Therapeutics in a research report on Wednesday, June 5th. Finally, ValuEngine downgraded Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 12th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $18.06.
In related news, Director Burke W. Whitman acquired 4,945 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was acquired at an average cost of $10.07 per share, for a total transaction of $49,796.15. Following the completion of the acquisition, the director now directly owns 21,612 shares of the company’s stock, valued at approximately $217,632.84. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO John F. Crowley sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $12.54, for a total transaction of $250,800.00. Following the transaction, the chief executive officer now owns 770,194 shares in the company, valued at approximately $9,658,232.76. The disclosure for this sale can be found here. 2.50% of the stock is currently owned by insiders.
Large investors have recently made changes to their positions in the stock. Point72 Hong Kong Ltd acquired a new stake in Amicus Therapeutics in the second quarter worth approximately $49,000. US Bancorp DE boosted its stake in Amicus Therapeutics by 50.9% during the 2nd quarter. US Bancorp DE now owns 4,896 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 1,651 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Amicus Therapeutics during the 2nd quarter valued at $73,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. acquired a new position in shares of Amicus Therapeutics during the 2nd quarter valued at $122,000. Finally, Weil Company Inc. bought a new stake in shares of Amicus Therapeutics in the 2nd quarter worth $125,000.
NASDAQ FOLD traded up $0.04 on Friday, hitting $9.97. The stock had a trading volume of 2,221,282 shares, compared to its average volume of 3,216,932. Amicus Therapeutics has a one year low of $8.27 and a one year high of $14.61. The company has a quick ratio of 6.97, a current ratio of 7.09 and a debt-to-equity ratio of 0.31. The stock has a market cap of $2.42 billion, a price-to-earnings ratio of -7.50 and a beta of 1.65. The company’s 50-day moving average is $10.72 and its two-hundred day moving average is $12.27.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
Featured Article: What is the definition of a trade war?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.